GlassScriptPhysician profile
Carl S High
NPI 1700808177
$877.19
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $272 · 2021: $225 · 2022: $125 · 2023: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $143.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $136.40 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $121.06 | 2019-2023 | |
| Amgen INC. | $110.08 | 2020-2021 | |
| Amarin Pharma, INC. | $106.18 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $65.94 | 2020-2022 | |
| Dexcom, INC. | $51.59 | 2021-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $40.81 | 2021-2023 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $36.94 | 2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $30.99 | 2020 | |
| Mylan Specialty L.P. | $27.58 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.01 | 2023 | Hyqvia |
| Neurocrine Biosciences, INC. | $19.93 | 2023 | Ingrezza |
| Ultragenyx Pharmaceutical INC. | $18.24 | 2022 | |
| Philips North America LLC | $17.38 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $16.20 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $16.10 | 2020 | |
| Merck Sharp & Dohme LLC | $15.02 | 2022 | |
| Lilly USA, LLC | $14.16 | 2022 | |
| Daiichi Sankyo INC. | $12.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl High listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.